Description
SR9009 (Stenabolic) is a synthetic agonist of the Rev-erbα receptor and mechanistically belongs to the class of circadian clock modulators. Despite being listed alongside SARMs, SR9009 doesn’t act via the androgen receptor; it modulates the central circadian clock and peripheral metabolism.
Per study reports SR9009 activates the Rev-erbα receptor, which represses transcription factors of the cellular clock (BMAL1, CLOCK). The consequences in preclinical models are improved lipid and glucose profile, increased mitochondrial biogenesis in skeletal muscle, and in mouse studies (Solt et al 2012, Nature) increased running endurance similar to Cardarine.
The central limitation of SR9009 is oral pharmacokinetics: in animal studies the substance has poor oral bioavailability (under 3% in mice) and a half-life of only 4-5 hours. This makes oral dosing practically problematic - most preclinical research administered SR9009 intraperitoneally.
In the recreational community SR9009 is nonetheless used orally, with 2-3 daily doses to compensate the short action window. The actual biological activity in oral application is debated - a 2019 study (Dierickx et al, PNAS) indicated that many in-vitro effects of SR9009 may not run specifically via Rev-erbα but be off-target.
SR9009 is on the WADA banned list.
You can order SR9009 as oral tablets in one bottle with 20mg per tablet.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
SR9009 sits in the mid range of the risk scale. The central open point is less an acute safety risk than the unclear biological activity and thin data situation.
Documented in studies and the literature:
- Poor oral bioavailability: in animal studies oral bioavailability is under 3%, and most preclinical research was conducted intraperitoneally - the actual effect in oral application is debated.
- Off-target effects: a 2019 study indicated that many in-vitro effects of SR9009 may not run specifically via Rev-erbα but be off-target.
- Sleep disturbance: as a circadian clock modulator, late dosing is associated with sleep disturbances in the recreational community.
- No HPG suppression: SR9009 is not an AR agonist, and no PCT is required.
Monitoring via bloodwork is recommended. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists - Nature 2012, Solt et al: first full characterization of SR9009’s effects on metabolism and running endurance in mice.
- Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy - Nature Medicine 2013, Woldt et al: SR9009 increases skeletal muscle mitochondrial biogenesis and boosts exercise capacity.
- SR9009 has REV-ERB-independent effects on cell proliferation and metabolism - PNAS 2019, Dierickx et al: important critique study, many in-vitro effects of SR9009 do not run specifically via Rev-erb.
- REV-ERBβ is required to maintain normal wakefulness and the wake-inducing effect of dual REV-ERB agonist SR9009 - Biochemical Pharmacology 2018, Amador et al: SR9009 has a wake-promoting effect, relevant to its circadian action profile.
